CancerDrs

Ovarian Cancer clinical trials

300 actively recruiting ovarian cancer trials in the United States. Epithelial ovarian cancer and related gynecologic malignancies. Trials focus on PARP inhibitors, immunotherapy, and maintenance strategies.

Data from ClinicalTrials.gov · last refreshed · Ovarian Cancer stats on SEER

81
Phase 1
100
Phase 2
18
Phase 3
101
Other

Ovarian Cancer by the numbers (U.S.)

20,890
Estimated new cases (2025)
12,730
Estimated deaths (2025)
51.6%
5-year relative survival
63
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse ovarian cancer trials by state

Texas 136 New York 110 California 103 Florida 92 Ohio 82 Massachusetts 79 Virginia 74 Pennsylvania 72 Michigan 63 Minnesota 58 Tennessee 55 Illinois 53 North Carolina 50 Washington 46 Missouri 45 New Jersey 44 Maryland 42 Colorado 41 Arizona 38 Oklahoma 38 Oregon 38 Georgia 37 Connecticut 34 Wisconsin 34 Utah 31 Alabama 29 Indiana 29 Kentucky 27 Louisiana 21 South Carolina 21 Nebraska 18 Rhode Island 18 Arkansas 17 Kansas 17 Iowa 16 South Dakota 16 New Mexico 15 Nevada 14 Maine 12 District of Columbia 11 North Dakota 11 Montana 10 Mississippi 8 New Hampshire 8 West Virginia 8 Alaska 7 Delaware 7 Hawaii 7 Idaho 7 Wyoming 3 Vermont 2

Top trials by phase + site coverage

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Anchorage Associates in Radiation Medicine — Anchorage, Alaska
  • Anchorage Radiation Therapy Center — Anchorage, Alaska

+ 1201 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…

Sponsor: NRG Oncology
NCT ID: NCT06580314
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Anchorage Associates in Radiation Medicine — Anchorage, Alaska
  • Alaska Breast Care and Surgery LLC — Anchorage, Alaska

+ 655 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…

Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Locations:
  • Children's Hospital of Alabama — Birmingham, Alabama
  • USA Health Strada Patient Care Center — Mobile, Alabama
  • Anchorage Associates in Radiation Medicine — Anchorage, Alaska

+ 563 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part o…

Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Locations:
  • Children's Hospital of Alabama — Birmingham, Alabama
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • USA Health Strada Patient Care Center — Mobile, Alabama

+ 187 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

This is a clinical study that has two parts. It is testing a potential new medicine called Sofetabart Mipitecan (LY4170156) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A looks at participants whos…

Sponsor: Eli Lilly and Company
NCT ID: NCT07213804
Locations:
  • University of Alabama at Birmingham — Birmingham, Alabama
  • HonorHealth — Phoenix, Arizona
  • Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center — Burbank, California

+ 78 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallo…

Sponsor: AbbVie
NCT ID: NCT05445778
Locations:
  • Usa Mitchell Cancer Institute /ID# 269661 — Mobile, Alabama
  • Honorhealth Virginia G. Piper Cancer Care Network - Biltmore /ID# 269987 — Phoenix, Arizona
  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 269573 — Irvine, California

+ 71 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadj…

Sponsor: GOG Foundation
NCT ID: NCT05659381
Locations:
  • City of Hope — Duarte, California
  • University of California San Diego Moores Cancer Center — La Jolla, California
  • Hoag Memorial Hospital Presbyterian — Newport Beach, California

+ 56 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Locations:
  • HonorHealth — Phoenix, Arizona
  • University of Arkansas — Little Rock, Arkansas
  • UCLA Health — Los Angeles, California

+ 35 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice…

Sponsor: Genelux Corporation
NCT ID: NCT05281471
Locations:
  • The University of South Alabama, Mitchell Cancer Institute — Mobile, Alabama
  • University of Arizona Cancer Center — Tucson, Arizona
  • City of Hope — Duarte, California

+ 28 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer get…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06824467
Locations:
  • University of Alabama at Birmingham ( Site 0006) — Birmingham, Alabama
  • Alaska Women's Cancer Care ( Site 0096) — Anchorage, Alaska
  • Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0001) — New Haven, Connecticut

+ 27 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expr…

Sponsor: Daiichi Sankyo
NCT ID: NCT06819007
Locations:
  • Scripps Clinic — La Jolla, California
  • Broward Health Medical Center — Fort Lauderdale, Florida
  • Jupiter Medical Center — Jupiter, Florida

+ 21 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant…

Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04575935
Locations:
  • University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
  • Cleveland Clinic Foundation - Florida — Weston, Florida
  • Massachusetts General Hospital — Boston, Massachusetts

+ 10 more sites in the U.S.

View on ClinicalTrials.gov →

Showing 12 of 300 trials. See all on ClinicalTrials.gov

Before you contact a trial site

Trial eligibility criteria are specific and strict. Reading them carefully before calling a site saves time. These guides walk through what to look for.

How to read clinical trial eligibility →

Inclusion, exclusion, biomarker requirements, performance status, and prior-therapy rules.

 How to find a clinical trial →

Search strategy, matching services, and when to involve your oncologist.

 Clinical trial phases explained →

Phase 1 through 4, what each means for patients.

 Insurance coverage for clinical trials →

The ACA requires coverage of routine patient costs. How to appeal denials.

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-11